This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arena Pharma Denied Request Added Market Exclusivity for Weight-Loss Drug

The FDA denied two Citizen Petitions -- including one filed by Eisai and Arena Pharmaceuticals  (ARNA - Get Report) -- requesting additional New Chemical Entity (NCE) market exclusivity to make up for the commercial launch delay caused by need to wait for DEA scheduling.

Eisai and Arena received FDA approval to market the weight-loss drug Belviq on June 27, 2012. The approval data also triggered the start of the drug's five-year market exclusivity as a New Chemical Entity (NCE), per FDA regulations. However, FDA would not allow Eisai and Arena to start selling Belviq until DEA scheduling was completed, given the drug's abuse potential. The final order for DEA scheduling was filed on June 7, 2013, meaning Eisai and Arena lost almost one year of market exclusivity.

In a Citizen Petition, Eisai argued the clock on NCE market exclusivity should start no the date the drug can be marketed, not the formal approval date. 

In response, the FDA said no.

Here's a link to the FDA's ruling on the Citzen Petitions.

FDA Law Blog has also posted on the matter. 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Markets

DOW 18,067.03 +26.66 0.15%
S&P 500 2,116.31 +4.58 0.22%
NASDAQ 5,096.98 +14.0510 0.28%

Adam's Tweets

Partners Compare Online Brokers

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs